OTC
ACHN

Opera Trading Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Opera Trading Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,106
Closed -$8K – 179
2018
Q3 		$8K Buy
+2,106
New +$6.28K ﹤0.01% 170

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Opera Trading Capital's ACHN Position: Q4 2018 in Review

Opera Trading Capital sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 2,106 shares — an estimated $8K sold.

Opera Trading Capital first reported a position in ACHN in Q3 2018 and held it in 1 quarter. The position peaked at $8K in Q3 2018. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

  • Opera Trading Capital reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Opera Trading Capital sold 2,106 Achillion Pharmaceuticals shares in Q4 2018, an estimated $8K.
  • Opera Trading Capital first reported a position in Achillion Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Opera Trading Capital's Achillion Pharmaceuticals position peaked at $8K in Q3 2018.
  • 121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.